{"title":"Associations Between <i>FTO</i> Polymorphisms and Neuroblastoma Risk in Chinese Children.","authors":"Peiqi Liu, Yue Li, Yong Li, Li Li, Jiwen Cheng, Suhong Li, Jiao Zhang, Haixia Zhou, Yunlong Huo, Zhonghua Yang, Jing He, Ran Zhang","doi":"10.2147/PGPM.S488314","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neuroblastoma (NB) is a malignancy of neural crest cells that primarily affects children. Single nucleotide polymorphisms (SNPs) in the fat mass and obesity-associated (<i>FTO</i>) gene, a well-conserved gene, have been implicated in tumorigenesis. However, there is currently insufficient evidence to establish the relationship between <i>FTO</i> gene SNPs and susceptibility to NB.</p><p><strong>Methods: </strong>A TaqMan assay was conducted to examine the potential associations between <i>FTO</i> gene SNPs and the risk of NB in a cohort of 898 patients and 1734 controls from eight medical centers in China. Additionally, stratification analysis was performed to evaluate the relationship between the selected <i>FTO</i> SNPs and the susceptibility to NB among various subgroups.</p><p><strong>Results: </strong>No significant association was found between the selected <i>FTO</i> polymorphisms and the risk of NB in either the single locus analysis or the combined analysis.</p><p><strong>Conclusion: </strong>However, our study reveals that individuals with retroperitoneal NB and those with stage III+IV NB are more prone to exhibit <i>FTO</i> SNPs compared to other patients. Moreover, participants with the <i>FTO</i> rs8047395 GG genotype displayed a higher likelihood of developing stage III+IV NB in comparison to other participants.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":"18 ","pages":"143-151"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126111/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics & Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PGPM.S488314","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Neuroblastoma (NB) is a malignancy of neural crest cells that primarily affects children. Single nucleotide polymorphisms (SNPs) in the fat mass and obesity-associated (FTO) gene, a well-conserved gene, have been implicated in tumorigenesis. However, there is currently insufficient evidence to establish the relationship between FTO gene SNPs and susceptibility to NB.
Methods: A TaqMan assay was conducted to examine the potential associations between FTO gene SNPs and the risk of NB in a cohort of 898 patients and 1734 controls from eight medical centers in China. Additionally, stratification analysis was performed to evaluate the relationship between the selected FTO SNPs and the susceptibility to NB among various subgroups.
Results: No significant association was found between the selected FTO polymorphisms and the risk of NB in either the single locus analysis or the combined analysis.
Conclusion: However, our study reveals that individuals with retroperitoneal NB and those with stage III+IV NB are more prone to exhibit FTO SNPs compared to other patients. Moreover, participants with the FTO rs8047395 GG genotype displayed a higher likelihood of developing stage III+IV NB in comparison to other participants.
期刊介绍:
Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.
In particular, emphasis will be given to:
Genomic and proteomic profiling
Genetics and drug metabolism
Targeted drug identification and discovery
Optimizing drug selection & dosage based on patient''s genetic profile
Drug related morbidity & mortality intervention
Advanced disease screening and targeted therapeutic intervention
Genetic based vaccine development
Patient satisfaction and preference
Health economic evaluations
Practical and organizational issues in the development and implementation of personalized medicine programs.